Ascendis Pharma's Initial Dose Escalation Results from the O

COPENHAGEN, Denmark, April 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that initial dose escalation data from the Company's ongoing Phase 1/2 IL-Believe Trial of TransCon

Related Keywords

Munich , Bayern , Germany , Ukraine , Palo Alto , California , United States , Russia , Denmark , Heidelberg , Baden Wüberg , Redwood City , New Jersey , Berlin , Chicago , Illinois , Copenhagen , Køavn , American , Ascendis Pharma , Tim Lee , Stina Singel , Melinda Baker , Patti Bank , Head Of Clinical Development , American Society Of Clinical Oncology , Exchange Commission , Ascendis Pharma Group , Believe Trial , American Society , Clinical Oncology , Executive Vice President , Clinical Development , Ascendi Annual Report , Ascendis , Dharma , Nitial , Nose , Escalation , Results , Rom , Ngoing , Hase , Trial , Transcon , Accepted , Nline , Publication , Disco , 023 ,